Off-label use of "smart drugs" — pharmaceuticals meant to treat disorders, such as attention deficit hyperactivity disorder, narcolepsy and Alzheimer's disease — are becoming increasingly popular among college students hoping to get ahead. The drugs are often used because they improve focus and alertness for longer periods of time. But is this cheating? Should their use as cognitive enhancers be approved by the Food and Drug Administration, the medical community and society? Do the benefits outweigh the risks?

There's not widespread agreement, and various experts have various points of view. This "2-Minute Debate" is part of a series co-produced by Intelligence Squared U.S. and Newsy.

The panel:

Dr. Anjan Chatterjee, professor at University of Pennsylvania and chair of neurology at Pennsylvania Hospital

Nita Farahany, professor at Duke University and director of Duke Science & Society

Eric Racine, director of the Neuroethics Research Unit at IRCM

Nicole Vincent, associate professor of philosophy, law and neuroscience at Georgia State University

Watch the full debate at Intelligence Squared U.S.

About the Author

Keep Reading

Blooper celebrates the Atlanta Brave’s 5-0 win over the New York Mets during a MLB game Wednesday, June 18, 2025 at Truist Park. This year, the venue is a first-time host of the MLB All-Star game. (Daniel Varnado for the AJC)

Credit: Daniel Varnado for the AJC

Featured

Rebecca Ramage-Tuttle, assistant director of the Statewide Independent Living Council of Georgia, says the the DOE rule change is “a slippery slope” for civil rights. (Hyosub Shin/AJC)

Credit: HYOSUB SHIN / AJC